financetom
Business
financetom
/
Business
/
Anglo Teck: A New Copper Empire Is Quietly Taking Shape
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Anglo Teck: A New Copper Empire Is Quietly Taking Shape
Sep 11, 2025 11:54 AM

Anglo American Plc ( AAUKF )'s (OTCPK:NGLOY) (OTCPK:AAUKF) bold tie-up with Teck Resources Ltd ( TECK ) is shaping up to be more than just another mining merger—it's a copper power play that could redraw the global commodities map.

JPMorgan analyst Dominic O’Kane noted that the combined Anglo-Teck will be built on a base where copper already makes up about 66% of EBITDA. That figure could jump to 72%.

Track TECK stock here.

Read Also: Anglo American, Teck Resources Strike $53 Billion Merger To Form Global Critical Minerals Giant

Synergies Worth Their Weight In Copper

Unlike BHP Group Ltd ( BHP )'s failed 2024 bid, which lacked operational overlap, O’Kane says Anglo-Teck's portfolio is almost engineered for synergy. Management estimates $800 million a year in savings within four years, with 80% realized by year two.

But the real kicker is copper growth—the rise from 66% to 72%. O’Kane needs Anglo to follow through on its plans to divest from coal and De Beers. That percentage could then surge even further post-2030 as production ramps at key Chilean assets.

Adjacent assets like Collahuasi and Quebrada Blanca could add 175,000 tonnes annually at an industry-beating $11,000 per tonne capital intensity, generating $1.4 billion in incremental EBITDA.

Growth economics such as these could shape Anglo-Teck into a copper empire as they sharply undercut LatAm's typical $40,000 per tonne costs. Anglo-Teck could have a scale and cost advantage that rivals won’t be able to match easily, noted O’Kane.

Low Debt, High Payouts, And A Bet On Prices

The merger isn't just about growth; it's also about cash returns, says O’Kane. Anglo plans a $4.5 billion dividend for its shareholders, funded largely by Teck's balance sheet, leaving pro forma leverage at less than 1x EBITDA in 2027—even before any proceeds from coal and diamond asset sales.

While the plan carries some risk if commodity prices tumble, the capital discipline and balance sheet strength should cushion shocks, he notes.

In a sector where scale often comes at the expense of synergy, Anglo-Teck may have cracked the code: a low-capital copper growth engine that could make it the envy of global miners.

Read Next:

Nil Premium Merger Of Equals Is Strategically Excellent For Anglo, Says Analysts

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Brazil Inc places cautious bet on Argentina turnaround under Milei
Brazil Inc places cautious bet on Argentina turnaround under Milei
Feb 17, 2025
* Brazil companies make new investments or consider ramping up * Economic change is spurring confidence in neighbor * Sectors from consumer goods to oil cite interest By Luciana Magalhaes SAO PAULO, Feb 17 (Reuters) - Brazilian companies are scoping out acquisition targets in Argentina, while beefing up staff and stores in a cautious bet on President Javier Milei's aggressive...
Brazil Inc places cautious bet on Argentina turnaround under Milei
Brazil Inc places cautious bet on Argentina turnaround under Milei
Feb 17, 2025
SAO PAULO (Reuters) - Brazilian companies are scoping out acquisition targets in Argentina, while beefing up staff and stores in a cautious bet on President Javier Milei's aggressive economic reforms that are beginning to stabilize the crisis-stricken economy. Brazilian firms, including consumer goods, services, oil and tech, told Reuters they are looking to launch new ventures or drafting expansion plans...
Teva Pharm CEO calls for faster US generic drug approvals
Teva Pharm CEO calls for faster US generic drug approvals
Feb 17, 2025
TEL AVIV, Feb 17 (Reuters) - U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding freezes, the CEO of Israel's Teva Pharmaceutical Industries said on Monday. In the FDA (Food and Drug Administration), there is no speed. I would like them to do things on a regular time because the more...
Teva Pharm CEO calls on Trump for faster US drug approvals
Teva Pharm CEO calls on Trump for faster US drug approvals
Feb 17, 2025
* Says supplies generic drugs in US cost effectively * Says produces high volumes in the US * Bullish on future earnings on basis of innovative portfolio (Adds quotes from news conference, context, paragraph 7 onwards) By Steven Scheer TEL AVIV, Feb 17 (Reuters) - U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some...
Copyright 2023-2026 - www.financetom.com All Rights Reserved